Background: Misfolding and aggregation of proteins into ordered fibrillar structures is associated with a number of severe pathologies, including Alzheimer's disease, prion diseases, and type II diabetes. The rapid accumulation of knowledge about the sequences and structures of these proteins allows using of in silico methods to investigate the molecular mechanisms of their abnormal conformational changes and assembly. However, such an approach requires the collection of accurate data, which are inconveniently dispersed among several generalist databases.
Results: We therefore created a free online knowledge database (AMYPdb) dedicated to amyloid precursor proteins and we have performed large scale sequence analysis of the included data. Currently, AMYPdb integrates data on 31 families, including 1,705 proteins from nearly 600 organisms. It displays links to more than 2,300 bibliographic references and 1,200 3D-structures. A Wiki system is available to insert data into the database, providing a sharing and collaboration environment. We generated and analyzed 3,621 amino acid sequence patterns, reporting highly specific patterns for each amyloid family, along with patterns likely to be involved in protein misfolding and aggregation.
Conclusion: AMYPdb is a comprehensive online database aiming at the centralization of bioinformatic data regarding all amyloid proteins and their precursors. Our sequence pattern discovery and analysis approach unveiled protein regions of significant interest. AMYPdb is freely accessible 1.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442844 | PMC |
| http://dx.doi.org/10.1186/1471-2105-9-273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A mini review of leveraging biobanking in the identification of novel biomarkers in neurological disorders: insights from a rapid single-cell sequencing pipeline.
Front Neurosci
December 2024
Department of Neurology, College of Medicine, The Ohio State University, Columbus, OH, United States.
Recent successes in the identification of biomarkers and therapeutic targets for diagnosing and managing neurological diseases underscore the critical need for cutting-edge biobanks in the conduct of high-caliber translational neuroscience research. Biobanks dedicated to neurological disorders are particularly timely, given the increasing prevalence of neurological disability among the rising aging population. Translational research focusing on disorders of the central nervous system (CNS) poses distinct challenges due to the limited accessibility of CNS tissue pre-mortem.
View Article and Find Full Text PDFAssessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by cardiovascular magnetic resonance quantitative stress perfusion.
J Cardiovasc Magn Reson
December 2024
Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, China; Clinical Research Center for Medical Imaging in Hunan Province, Changsha, China. Electronic address:
Background: Cardiac involvement in light chain amyloidosis (AL) is the main determinant of prognosis. Amyloid can be deposited in the extracellular space and cause an increase in extracellular volume fraction (ECV). At the same time, amyloid can also be deposited in the wall of small vessels and cause microvascular dysfunction.
View Article and Find Full Text PDFConsidering Biomarkers of Neurodegeneration in Alzheimer's Disease: The Potential of Circulating Cell-Free DNA in Precision Neurology.
J Pers Med
November 2024
Department of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA.
Article Synopsis
- Neurodegenerative diseases like Alzheimer's are on the rise due to an aging population and lack of effective early treatments, making early detection crucial for better outcomes.
- Current diagnostics primarily focus on observable symptoms and existing neuronal damage, while specific biomarkers for Alzheimer's are too narrow, and general biomarkers like NfL lack precise insights.
- Circulating cell-free DNA (cfDNA) shows promise as a minimally invasive early detection biomarker, providing both general and disease-specific information, but further research is essential to overcome technical challenges and establish its clinical use.
Aggregating amyloid resources: A comprehensive review of databases on amyloid-like aggregation.
Comput Struct Biotechnol J
December 2024
Clinical Research Centre, Medical University of Białystok, Białystok, Poland.
Protein aggregation is responsible for several degenerative conditions in humans, and it is also a bottleneck in industrial protein production and storage of biotherapeutics. Bioinformatics tools have been developed to predict and redesign protein solubility more efficiently by understanding the underlying principles behind aggregation. As more experimental data become available, dedicated resources for storing, indexing, classifying and consolidating experimental results have emerged.
View Article and Find Full Text PDFTuning multispectral fluorescence quantum dot-based identification of short-length amyloid β peptides by applying Cu(II) ions.
Mikrochim Acta
October 2024
Chair of Medical Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664, Warsaw, Poland.
Currently available methods for detecting amyloid β (Aβ) derivatives are mainly dedicated to determining the long forms Aβ and Aβ. At the same time, the number of physiologically occurring Aβ analogs is much higher, including those truncated at the N- and C-termini. Their identification using standard methods is challenging due to the structural similarity of various Aβ analogs, but could highly benefit from both biomarkers discovery and pathophysiological studies of Alzheimer's disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!